Tbh if we had nothing else the 62% would be a "better than nothing" result. It's not a failure per se. Its just that at least at this point the others seem better...
I give it a chance to be 'my' dose, at some point between now and this time next year, for two main reasons:
- Those coldchain issues are less intensive than the BNT/etc, an issue we identified early on[1]
- The vastly higher number of doses already pre-paid for by the UK government[2] which, in light of other political dealings, is likely to send us down an 'in for a penny, in for a pound' route even if it's not the ideal resolution.
But that's just my mental musings on the current situation. I'm quite sure that by the time this resolves unto my lowly priority
much of my above reasoning will be overturned, even without your quite reasonable additional clinical clincher which I accept.
(Interestingly, as well, there has been state-sponsored (<-highly suspected to be that, at least) hacking of the Pfizer study info as submitted onto (I think it was) the EMA servers, recently reported. Added to other incidents like the earlier spearphishing attack on worldwide coldchain companies and the prior invasion of data in various vaccine developers at an early stage, I suspect that there may be concerns about all kinds of things from unlevel playing-fields during the initial rush to develop to future possible selective data-dumps aimed at skewing public opinion. I'm far more sure that this will emerge as 'a thing' than any particular manufacturer will be behind my own shot in the arm, if I ever get one... )
[1] I think Gamaleya needs only
fridge tech, in its portable form, but ruling that out for obvious reasons.
[2] Also it's a Oxford Uni, thing whether that drove that initial decision to pre-fund that way or will take part in the final national decision.